atezolizumab
roche
['sclc', 'atezo', 'impact,(-impacte),(-impacti),(-impactf)']
poster at #esmo22 by drs. et al showing #sclc treatment patterns in europe over time. ema approval of atezolizumab was not until 2019 and use of first line chemo-immunotherapy rose to 28% in 2020 and 46% in 2021. eap and reimbursement with clear impact on use. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him